ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. reported a net loss of $101.7 million for fiscal year 2025, driven by total operating expenses of $104.0 million, primarily from research and development ($77.0 million) and general and administrative costs ($23.9 million). The company generated no revenue, resulting in a loss from operations of $104.0 million. Interest income of $4.0 million partially offset the operating loss. Cash used in operating activities was $84.1 million, while investing activities provided $82.6 million mainly from investment maturities. The company ended the year with $59.0 million in total assets, including $16.4 million in cash and cash equivalents and $28.4 million in short-term investments. Total liabilities were $33.1 million, with stockholders' equity of $26.0 million. The net loss per share was $2.00 for both basic and diluted calculations.

Key Takeaways